TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05185765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: Samples will be provided one by one labeled with an unique code. The mastication and expectorated sample will be given in replicate.
Study: NCT05453097

Intervention type: DIAGNOSTIC_TEST
Intervention: Selvester QRS Score with Preoperative ECG
Description: Selvester QRS score will be calculated with the preoperative ECG of the patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Selvester QRS Score with Preoperative ECG
Description: Selvester QRS score will be calculated with the preoperative ECG of the patients.
Study: NCT06156332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surufatinib、serplulimab
Description: surufatinib:~250 mg (5 capsules) once a day, Q3W, continued until the patient developed disease progression or met other protocol criteria for discontinuation of study treatment; If the patient vomits after taking the medicine, there is no need to take the supplement; The missed dose should not be added the next day, and the next prescribed dose should be taken as usual.~serplulimab:~300mg fixed dose, intravenous infusion, d1, Q3W; Continued administration until the patient developed disease progression or met other protocol criteria for discontinuation of study therapy.~Imaging was used every 6 weeks (±7 days) to evaluate tumor status until disease progression (RECIST 1.1) or death (during patient treatment), and tumor treatment and survival status after disease progression were recorded. The changes of neuroendocrine tumor markers were detected after treatment.
Study: NCT05186675

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: superselective adrenal arterial embolization
Description: Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure
Study: NCT06432855

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: 20 ml-blood sample

Intervention type: OTHER
Group type: OTHER
Intervention: saliva collection
Description: saliva sample
Study: NCT04478812

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single Group Assignment
Description: Tbit™ System will detect S100B and GFAP concentrations with the blood specimen collected
Study: NCT05291611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online-based Cognitive-behavioral Therapy for OCD
Description: 26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
Study: NCT05798455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Pentaborate
Description: Capsules containing sodium pentaborate pentahydrate 500, 1000 and 1500 mg
Study: NCT04576078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral nefopam
Description: Oral administration of nefopam 60mg 2 hours before the surgery following by 60mg each 8h for 24h. Oral nefopam is prepared ex-tempore from the intravenous formulation adding a taste masking compound by a non-caring nurse following detailed instructions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of a placebo 2 hours before the surgery following by one administration each 8h for 24h. Oral placebo is prepared ex-tempore with a taste masking compound by a non-charge nurse following detailed instructions
Study: NCT04843644

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: usual care
Study: NCT06358586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tachipirina® 120 mg/5 mL oral suspension, new flavour
Description: A single oral dose of the Tachipirina® 120 mg/5 mL oral suspension(10 mL) will be administered to healthy paediatric volunteers under fasting conditions for at least 1 h before IMP administration until completion of palatability assessment.
Study: NCT05250999

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This program include balance exercises performed twice a week for 6 weeks, which consists of balance, progressive strength, and functional mobility training. Static exercise consists of heel and toe raises, one-legged stance for each limb, weight shifting forward, backward, sideward and diagonally, and turning the head to the left and then to the right keeping the feet together. This exercise comprises two 10-min sessions each, with eyes opened and eyes closed, respectively. Dynamic exercise comprises of walking, step-ups, and bipedal jumps for 10 min. Progressive balance exercises comprises of narrow walking, walking backward, walking sideward, stepping over obstacles, passing, throwing and catching a ball.
Study: NCT04156984

Intervention type: DRUG
Group type: OTHER
Intervention: Golimumab Prefilled Syringe
Description: See arm description

Intervention type: DRUG
Group type: OTHER
Intervention: Golimumab Prefilled Syringe
Description: See arm description
Study: NCT04803734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol Sulfate inhalation aerosol 108mcg per actuation
Description: MDI, 2 puffs, single dose, fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation
Description: MDI, 2 puffs, single dose, fasting
Study: NCT05354921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indwelling Catheter
Description: Patients in the experimental group will receive foley catheter upon admission, aseptically. The catheter will be discontinued on the morning following surgery. At TOH most (\>75%) hip fractures are treated within 48 hours of admission and 95% within 72 hours and hence the indwelling catheter is likely to stay in place for 3-4 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Catheterization
Description: Patients randomized to the intermittent catheterization group will have their PVR monitored every 8 hours pre-operatively. If PVR\>400 mL, an intermittent catheter will be used. If PVR\> 400 mL greater than 3 times pre-operatively, an indwelling catheter will be placed the fourth time. The indwelling catheter will be removed the morning of post-op day 1.~It is expected that a small percentage of patients in either group will not have a PVR\>400 mL preoperatively.~These patients will not be catheterized but will remain in the study. Post-operatively, both treatment groups will have their PVR monitored for 24 hours, or until PVR is less than 200 mL. If PVR\>400 mL and the patient is not able to void further, intermittent catheterization will be done every six hours as needed. If post-operative PVR\>400 mL greater than 3 times post-operatively, an indwelling catheter will be placed the fourth time.
Study: NCT05846061

Intervention type: OTHER
Intervention: Prevalence study population
Description: No intervention
Study: NCT05911061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
Description: boost with high dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)
Description: boost with low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: boost with Recombinant Variant COVID-19 Vaccine(sf9 cell)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: saline
Study: NCT05565079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regenerative tissue matrix and enamel matrix derivative
Description: Subjects in this group will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM) and a porcine-derived enamel matrix derivative (Emdogain).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Regenerative tissue matrix
Description: Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
Study: NCT05816707

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRF
Description: Teeth will be extracted a-traumatically as possible to avoid any soft tissue or bony damage.~The extracted sockets will be debrided by bone curettes and saline. The three extraction sockets will be divided into three groups: control group, curcumin group, and PRF group.~After curcumin/ PRF placement, all sockets will be closed by simple interrupted suture
Study: NCT05565079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regenerative tissue matrix
Description: Subjects in both groups will receive a coronally positioned tunnel with a regenerative tissue matrix (AlloDerm, RTM).
Study: NCT06322602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracranial Catheter Placement
Description: Undergo Ommaya reservoir placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo LP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo CSF sample collection
Study: NCT05816707

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Curcuma Longa gel
Description: Curcuma Longa gel

Intervention type: OTHER
Group type: OTHER
Intervention: extraction socket
Description: extraction socket

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: extraction socket
Description: extraction socket

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: extraction socket
Description: extraction socket
Study: NCT05830032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble corn fibre
Description: As a powdered beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: As a powdered beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soluble corn fibre and inulin
Description: As a powdered beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: As a powdered beverage
Study: NCT06398054

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: Ibuprofen 400 mg tablet
Study: NCT06322602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT05549310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal canula oxygen therapy
Description: At the beginning of the experiment we will choose the most suitable pressure and flow for the patient by titration，
Study: NCT06398054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine N-Butil Bromide
Description: Hyoscine N-Butil Bromide 10 mg two tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Two tablets
Study: NCT05871268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician Awareness
Description: The patients' pre-visit Control Preference Scale response are shared with their physician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The patients' pre-visit Control Preference Scale response are not shared with their physician.
Study: NCT06265259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Initiation of vasopressine as a first vasoconstrictive drug
Description: The group (arm 1) where vasopressin (1 amp in 50 mlN/S) (1st vasoconstrictor) will be administered first up to a maximum dose of 0.03 IU/min (2.3 ml/h) for the treatment of hemodynamic instability. Then, if the patient remains unstable, noradrenaline (2nd vasoconstrictor) will be started. The dose of vasopressin will not be increased further than the above mentioned limit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Initiation of noradrenaline as a first vasoconstrictive drug
Description: ii. In the group (arm 2) where the treatment of haemodynamic instability will be performed by first administering noradrenaline (1st vasoconstrictor) up to 0,5 mcg/kg/min and then, if the patient is still unstable, adding vasopressin (2nd vasoconstrictor) at a maximum dose of 0.03 IU/min (2.3ml/h). If haemodynamic instability persists, treatment will involve further increase of the noradrenaline dose.
Study: NCT05195801

Intervention type: DEVICE
Intervention: USG
Description: Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.

Intervention type: DEVICE
Intervention: USG
Description: Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
Study: NCT05721833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory
Description: Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive Bilevel Positive Pressure Ventilation
Description: Noninvasive Bilevel Positive Pressure Ventilation.
Study: NCT04608786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZKAB001 5mg/kg
Description: ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses
Study: NCT05383560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 Vaccine
Description: Omicron Variant-Matched Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 Vaccine
Description: Omicron Variant-Matched Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 Vaccine
Description: Omicron Variant-Matched Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MRNA-1273 Vaccine
Description: Moderna's commercial COVID-19 Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal Saline for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline for injection
Study: NCT05918549

Intervention type: DEVICE
Intervention: Motion Analysis in Musculoskeletal Oncology
Description: Noninterventional, prospective, multicenter pilot study of patients with primary and secondary musculoskeletal tumors designed to investigate functional outcomes after therapy using both subjective and quantitative motion detection techniques
Study: NCT05195801

Intervention type: DEVICE
Intervention: USG
Description: Optic Nerve Diameter will be measured in the intraoperative period and postoperative 1st month by ultrasonography method.
Study: NCT04753697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-93538
Description: Subcutaneous
Study: NCT05585398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Intradermal injections using different delivery methods (conventional needle and microneedles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Intradermal injections using different delivery methods (conventional needle and microneedles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Intradermal injections using different delivery methods (conventional needle and microneedles)
Study: NCT05567679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazverik
Description: Tazemetostat (Tazverik) 200 mg oral tablets; 800 mg by mouth twice daily for 28 days
Study: NCT05383560

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MRNA-1273.222 Vaccine
Description: Moderna's commercial COVID-19 Vaccine
Study: NCT04753697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous
Study: NCT05749354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: electroacupuncture
Description: Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture
Description: Electroacupuncture (EA) is a method of treating diseases by inserting a needle (usually a filiform needle) into the skin or tissue of a patient at a certain Angle, and then passing through the needle (sensing) micro-current waves of human bioelectricity to stimulate specific parts of the human body (acupoints).~1. Disposable sterile acupuncture filiform needle (0.16mm×13mm, 0.30mm×25mm, 0.30mm× 40mm), Guizhou Andi Medical Equipment Co, LTD, Guizhou Food and Drug Supervision and Equipment Production Xu 20170011.~2. Electroacupuncture apparatus: SDZ-Ⅱ electroacupuncture apparatus of Huatuo brand, Suzhou Medical Supplies Factory Co., LTD., Registration No. : 20172270675.~For non-acupoint group,the internal wire of the electroacupuncture instrument will be interrupted, no current passed through.
Study: NCT04941404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105 tablets
Description: Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.
Study: NCT05988190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contextual Word Learning Intervention
Description: Metalinguistic intervention consisting of meaning generation, explanation and feedback, with semantic diversity varying (no, medium, high).
Study: NCT05570890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical noise stimulation
Description: The intensity of electrical noise stimulation will be set at 90% of the sensory threshold of each participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical noise stimulation
Description: The intensity of electrical noise stimulation will be set at 90% of the sensory threshold of each participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Participants will not receive stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: Participants will not receive stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foam
Description: The foam will be used to make an unstable surface.